MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from marketable
securities
$574,454K
Proceeds from offerings,
net
$112,151K
Proceeds from exercise of
stock options
$4,962K
Net cash provided by
(used in) investing...
$217,998K
Net cash provided by
financing activities
$117,113K
Effect of exchange rate
changes on cash and cash...
$458K
Canceled cashflow
$356,456K
Increase (decrease) in
cash and cash...
$56,451K
Canceled cashflow
$279,118K
Purchase of marketable
securities
$355,657K
Purchases of property,
plant and equipment
$799K
Stock-based compensation
$53,707K
Interest receivable and
accretion of discounts on...
-$7,369K
Accounts payable and
accrued liabilities
$5,511K
Other liabilities
$3,199K
Depreciation of property,
plant and equipment
$2,543K
Non-cash operating lease
expense
$1,313K
Realized loss on
marketable securities
-$625K
Other receivables
-$104K
Unrealized foreign
exchange (gain) loss
-$73K
Net cash used in
operating activities
-$279,118K
Canceled cashflow
$74,444K
Net loss
-$345,910K
Deferred income tax
recovery
-$3,198K
Prepaid expenses and
other assets
$3,157K
Operating lease liability
-$1,297K
Back
Back
Cash Flow
source: myfinsight.com
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)